BioSenic SA is a leading biotech company specializing in the development of clinical assets issued from the allogeneic cell therapy platform ALLOB and from the Arsenic TriOxide (ATO) platform. Key target indications for the platforms include Graft versus Host Disease (GvHD), Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc) and high-risk tibial fractures.
Following the merger in October 2022, BioSenic SA combines the strategic positionings and strengths of Medsenic and Bone Therapeutics.
The merger also enables Biosenic SA to add to its innovative cell therapy platform and strong IP for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO.
More about the company